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Hantaviruses cause 2 zoonotic diseases, hemorrhagic 
fever with renal syndrome (HFRS) and hantavirus cardiopul-
monary syndrome. Infection is usually initiated after inhala-
tion of virus-contaminated rodent excreta. In addition to the 
zoonotic infection route, growing evidence suggests person-
to-person transmission of Andes virus. For this reason, we 
studied whether saliva from HFRS patients contained han-
tavirus. During an outbreak in northern Sweden of nephro-
pathia epidemica (NE), a milder form of hemorrhagic fever 
with renal syndrome, we collected saliva and plasma from 14 
hospitalized NE patients with veriﬁ  ed Puumala virus (PUUV) 
infection. PUUV RNA was detected in saliva from 10 patients 
(range 1,530–121,323 PUUV RNA copies/mL) by quantita-
tive reverse transcription–PCR. The PUUV S-segment se-
quences from saliva and plasma of the same patients were 
identical. Our data show that hantavirus RNA could be de-
tected in human saliva several days after onset of disease 
symptoms and raise the question whether interhuman trans-
mission of hantavirus may occur through saliva.
M
embers of the family Bunyaviridae cause severe and 
often fatal human diseases in a large and increasing 
number of persons worldwide each year (1). This family 
contains 5 genera, and the genus Hantavirus causes 2 fe-
brile illnesses: hemorrhagic fever with renal syndrome 
(HFRS) in Europe and Asia and hantavirus cardiopulmo-
nary syndrome (HCPS) in North and South America. Han-
taviruses are rodent-borne pathogens. In Sweden, Finland, 
Norway, Russia, and parts of central Europe, Puumala vi-
rus (PUUV) is endemic in bank voles (Myodes glareolus). 
PUUV causes nephropathia epidemica (NE), a milder form 
of HFRS. The most common symptoms of NE are fever, 
headache, nausea, vomiting, myalgia, abdominal pain, back 
pain, and visual disturbances (2). One third of the patients 
have hemorrhagic manifestations, 10%–20% have respira-
tory tract symptoms, and most have signs of renal failure 
(2). There is no effective treatment or available vaccine.
The most common route of hantavirus infection is in-
fectious aerosols originating from saliva, urine, and feces 
of infected rodents (1). Because rodent bites have been 
demonstrated to cause human hantavirus infections (3,4), 
saliva of hantavirus-infected rodents must contain infec-
tious virus. Infectious PUUV has been found in oropha-
ryngeal secretions from M. glareolus (5) and Andes virus 
(ANDV) RNA is present in saliva from infected pigmy rice 
rats (Oligoryzomys longicaudatus) (6). Furthermore, Sin 
Nombre virus RNA is present in saliva but not in urine and 
feces from deer mice (Peromyscus maniculatus) (7), con-
ﬁ  rming that hantaviruses are transmitted to humans through 
rodent saliva. However, person-to-person transmission has 
recently been documented for the ANDV that causes HCPS 
(8–13), and contaminated human saliva suggests a possible 
route of infection (13). For herpesviruses, such as Epstein-
Barr virus and herpesviruses-7 and -8, person-to-person 
transmission can occur from saliva (14–16), but human 
salivary secretions could also negatively modulate herpes-
virus infectivity as shown for herpesvirus-1 (17).
Because the saliva of hantavirus-infected rodents con-
tains infectious virus that is transmitted to humans (3,4,7) 
and person-to-person transmission is strongly suspected for 
ANDV (13), we studied whether the virus could be detect-
ed in saliva of hantavirus-infected patients. For this reason, 
we collected saliva from patients during an NE outbreak 
in northern Sweden and analyzed the samples for the pres-
ence and levels of PUUV RNA by using a real-time reverse 
transcription–PCR (RT-PCR) assay.
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Material and Methods
Collection of Human Saliva
Saliva was collected from PUUV-infected patients 
who were hospitalized from January through May 2007 at 
the Department of Infectious Diseases at Umeå University 
Hospital (Umeå, Sweden). Samples were obtained from pa-
tients with typical clinical symptoms of acute NE, which 
were veriﬁ  ed by detection of PUUV-speciﬁ  c immunoglob-
ulin (Ig) M in serum, a PUUV-speciﬁ  c real-time RT-PCR, 
or both. The collection was random, with no consideration 
of time of the day or food intake. The samples were only 
collected on 1 occasion during each patient’s hospitaliza-
tion by asking the patient to spit in a single-use plastic mug. 
The saliva was then removed with a syringe (5 mL; Bec-
ton Dickinson, Franklin Lakes, NJ, USA) and put in sterile 
plastic test tubes (Nunc, Roskilde, Denmark). The samples 
were immediately stored at –80°C until they were further 
analyzed. Plastic gloves and protective clothing were used 
during the procedure. A total of 9 samples were stored 
without additives, and 5 were diluted 1:3 in virus transport 
medium (2% HEPES, 10 μg/mL bovine serum albumin, 50 
μg/mL sucrose, 0.016 μg/mL fungizone, and 2.5 μg/mL 
garamycin) before storage. The project was approved by 
the Research Ethics Committee of Umeå University and all 
patients gave written and informed consent.
Real-Time RT-PCR
RNA from 140 μL of patient saliva and plasma was ex-
tracted by using a QIAamp Viral RNA kit (QIAGEN, Va-
lencia, CA, USA) according to the manufacturer’s instruc-
tions. The real-time RT-PCR was performed as previously 
described (18). Brieﬂ  y, the RNA was reverse-transcribed 
followed by a real-time PCR TaqMan assay in triplets 
with PUUV-speciﬁ  c primers and probe from the S seg-
ment (18). The real-time PCR was performed with an ABI 
Prism 7900HT Sequence Detection System 2.0 (Applied 
Biosystems, Foster City, California, USA). As internal 
positive control, we used a 72-bp Drosophila melanogaster 
fragment (nt position 1783–1854, GenBank accession no. 
NM_144343) cloned into a pcDNA3 vector (Invitrogen, 
Carlsbad, CA, USA). The plasmid was linearized with the 
restriction enzyme ApaI, and RNA was transcribed and pu-
riﬁ  ed as described (MEGAscript High Yield Transcription 
Kit, Ambion, Promega, Madison, WI, USA; www.megas-
oftware.net). The RNA control was diluted, added to pa-
tient sample, and used as template for quantitative real-time 
RT-PCR as described above. The primers and probe used 
for ampliﬁ  cation of control RNA was D. melanogaster 
forward primer 5′-AGGTGCCCGTGTGTATCCAT-3′ 
(900 nM), reverse primer 5′-GCTCGTCCTCCGCCTCAT-
3′ (900 nM) and probe 5′FAM-TACCACGAATCTGC-
GACATTACCAGGG-TAMRA-3′ (200 nM). Primers and 
probe were designed by using Primer Express version 2.0 
software (Applied Biosystems).
Immunoﬂ  uorescence Assay
An immunoﬂ  uoresence assay was performed as pre-
viously described (18). Brieﬂ  y, patient serum was added 
to spot slides covered with ﬁ  xed PUUV-infected Vero E6 
cells, and IgG levels were determined by using ﬂ  uorescein-
conjugated rabbit anti-human IgG (F202, DAKO A/S, 
Glostrup, Denmark) diluted in phosphate-buffered saline 
(PBS) with Evans blue. For IgM analysis, patient serum 
was pretreated with rheumatoid factor absorbent (Virion\
Serion GmbH, Würzburg, Germany) to eliminate possible 
interference of rheumatoid factor and PUUV-speciﬁ  c IgG. 
Slides were incubated overnight at 37°C, and antibody was 
detected by using ﬂ   uorescein-conjugated rabbit F(ab′)2 
anti-human IgM antibodies (F0317, DAKO A/S) diluted in 
PBS with Evans blue.
Sequencing
cDNA from patient saliva and plasma were ampliﬁ  ed 
by using Pfu DNA Polymerase (Fermentas Life Sciences, 
Helsingbord, Sweden), and the sequencing reactions were 
performed by using the Big Dye Terminator v 1.1 Cycle Se-
quencing kit (Applied Biosystems). The PCR and sequenc-
ing reactions were performed with primers from the S-seg-
ment. For patients 1 and 4, the primers for PCR was Puu1s 
(5′-CAAGAGGATATAACCCGCCA-3′) and Puu6as (5′-
GCCATCCCTGCAACATAGAT-3′) followed by Puu3s 
(5′-AACTGGGATTGAGCCAGATG-3′) and Puu5as (5′-
TGGGCATTCCTTTTCCATAA-3′) for sequencing. For 
patient 2, the primers for PCR was Puu1s and Puu5as fol-
lowed by Puu2s (5′-ACCCGCCATGAACAACAACT-3′) 
and Puu4as (5′-TAGGGCTTTCAAAATAATAGGTAG-
3′) for sequencing. Before the sequencing reaction, the 
PCR fragment was puriﬁ  ed by using a QIAquick PCR Puri-
ﬁ  cation kit (QIAGEN) and precipitated in ethanol. Assem-
bly, analysis, and alignment of sequences were performed 
by using Geneious Basic 3.0.6 (www.geneious.com) and 
BLAST (www.ncbi.nlm.nih.gov/blast).
Results
Hantavirus RNA in Saliva from NE Patients
We collected saliva 2–9 days after onset of symptoms 
from 14 hospitalized NE patients to determine whether 
hantaviruses were present in human saliva. All patients 
were positive for PUUV RNA in plasma by a real-time RT-
PCR, and 13 patients had PUUV-speciﬁ  c IgM antibodies 
in serum (Table). We then analyzed the saliva by real-time 
RT-PCR for the presence and levels of viral RNA. Saliva 
samples from 10 of 14 patients were positive for PUUV 
RNA (range 1,530–121,323 PUUV RNA copies/mL), 
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demonstrating that viral RNA could be detected in saliva 
during disease (Table). Furthermore, we detected no inhi-
bition of real-time RT-PCR in saliva or plasma when we 
analyzed our patient samples by using an internal positive 
control (data not shown). All patients were also IgG posi-
tive in serum with varying titers.
Sequencing of PUUV RNA in Saliva
To study in more detail whether the RNA we detected 
in saliva was truly speciﬁ  c, we sequenced regions of RT-
PCR products. Sequencing of ampliﬁ  cation products from 
saliva and plasma from 3 NE patients—patient 1 (GenBank 
accession nos. EU337014 and EU337015), patient 2 (Gen-
Bank accession nos. EU177629 and EU177630), and patient 
4 (GenBank accession nos. EU337016 and EU337017)—
demonstrated a PUUV S-segment sequence that was iden-
tical for each saliva/plasma pair (data not shown). When 
we compared the sequences for patients 1 and 4, we found 
24 mismatches in the 292-nt S-segment sequence, which 
clearly demonstrated that they were derived from different 
strains (Figure). The observed nucleotide mismatches did 
not result in different amino acid sequences. The sequence 
from patient 2 was from another S-segment region. All 
PUUV sequences from the NE patients were most closely 
related to PUUV strains from the disease-endemic region 
in northern Sweden and grouped with the northern branch 
of PUUV strains (19,20).
Respiratory Symptoms in NE patients
All 14 NE patients required hospital care and dis-
played the symptoms of NE. All survived and none had 
to be treated by dialysis. Seven patients had respiratory 
symptoms including cough, dyspnea, or both. In 2 of the 
patients with respiratory symptoms, a chest radiograph re-
vealed inﬁ  ltrates (data not shown). The 2 patients with the 
highest levels of viral RNA in saliva had dyspnea (patient 
1) and cough and lung inﬁ  ltrates (patient 2) (Table). All 
patients with respiratory symptoms, except 1 (patient 12), 
had PUUV RNA in their saliva.
Discussion
This investigation showed that hantavirus RNA could 
be detected in saliva from HFRS patients. We found PUUV 
RNA with varying PUUV genome copy numbers in the sa-
liva of most of the 14 hospitalized NE patients. Previously, 
we have shown that PUUV RNA in plasma decreases with 
time in the individual patient (18), and although we did 
not study this ﬁ  nding, PUUV in saliva likely would dis-
play similar kinetics. PUUV viremia is thought to persist 
for 5–7 days, but in our study, 1 patient had PUUV in both 
saliva and plasma 9 days after onset of symptoms. Fur-
thermore, we recently detected PUUV RNA in plasma 16 
days after ﬁ  rst appearance of disease (18). It would also be 
interesting to study whether nonhospitalized patients with 
milder symptoms also had PUUV RNA in their saliva. We 
do not know if PUUV RNA in saliva could originate from 
PUUV viremia, but the PUUV RNA detected in saliva was 
likely produced in salivary glands or through coughing. Re-
cently, ANDV antigen was found in secretory cells of the 
salivary glands of human patients (21). In our study, 7 of 
the patients had respiratory symptoms, and virus shedding 
in saliva is known to occur for several respiratory virus-
es, such as severe acute respiratory syndrome–associated 
coronavirus, respiratory syncytial virus, and human meta-
pneumovirus (22,23). Symptoms in the upper respiratory 
tract are also often present in NE (2,24), which makes our 
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Table. Comparison between detection of PUUV RNA in saliva and plasma and antibodies in serum samples from 14 patients with 
nephropathia epidemica* 
Patient
no. Sex Age,  y 
Date saliva collected 
(d of disease) 
PUUV RNA† in 
saliva, copies/mL 
PUUV RNA† in 
plasma,‡ copies/mL
PUUV IgM§ 
in serum‡ 
PUUV IgG titer 
in serum‡ 
1 M 65 6 121,323 959,294 + 40
2 M 64 2 66,994 117,562 + 80
3 M 33 5 44,898 40,427 + >640
4 F 38 6 17,516 1,381,413 + 40
5 F 59 9 9,582 3,724 + >640
6 M 54 5 6,372 26,626 – 320
7 M 39 7 3,745 189,233 + 320
8 M 28 5 2,589 36,231 + >640
9 F 26 5 2,163 54,315 + 80
10 F 39 5 1,530 3,044 + 80
11 M 38 6 0 1,952 ± >640
12 M 41 6 0 5,215 + 40
13 F 57 2 0 41,271 + 320
14 F 62 7 0 81,330 + 160
*PUUV, Puumala virus; Ig, immunoglobulin. 
†Detected by real-time reverse transcription–PCR. 
‡Most plasma and serum samples were collected the same day or within 1 day before or after the saliva sample and antibody was detected by 
immunofluorescence assay. 
§Serum was diluted 1:16 and scored as negative (–), positive (+), or weakly positive (±). Hantavirus RNA in Saliva from HFRS Patients
ﬁ  nding of PUUV in saliva credible. One may argue that 
NE, the HFRS endemic in northern and central Europe, is 
a different entity than HCPS, caused by Sin Nombre han-
tavirus and ANDV, and that the ﬁ  nding of viral RNA in 
saliva from NE patients is a pure coincidence. However, 
NE in Scandinavia shows several common characteristics 
with HCPS in the Americas. For example, pulmonary in-
volvement and respiratory symptoms are common in NE. 
In addition, radiologic examination–detectable inﬁ  ltrates, 
decreased pulmonary function, and a local inﬂ  ammatory 
response in the lungs have previously been demonstrated 
(25–28).
Could hantaviruses in human saliva be infectious and 
initiate infection? Today, the only hantavirus suggested to 
be transmitted between humans is ANDV (8–13). By using 
sophisticated epidemiologic data, Ferres et al. showed that 
the risk for HCPS caused by ANDV was higher among sex 
partners of the index case than among other household con-
tacts (13). These investigators suggested that ANDV needs 
close person-to-person contact, such as sexual relations or 
deep kissing, to be transmitted between humans (13). Our 
ﬁ  nding of hantavirus in saliva support the conclusion that 
hantavirus infection could be transmitted between humans 
through saliva, such as during kissing or coughing. Howev-
er, we do not know at this stage whether the hantavirus RNA 
in saliva detected in our study is infectious. When we tried to 
infect bank voles with human PUUV RNA–positive saliva, 
no seroconversion was found after 21 days (J. Hardestam et 
al., unpub. data). Furthermore, we have not been success-
ful in isolating PUUV from saliva specimens by infecting 
Vero E6 cells. Clinical isolates of hantaviruses do not grow 
readily on cell lines, and mutations of the noncoding regions 
were shown to be needed for the PUUV strain Kazan, origi-
nally isolated from bank voles, to grow in Vero E6 cells (29). 
The only human PUUV isolate from Sweden, PUUV strain 
Umeå/hu, adapted to growth in Vero E6 cells, was isolated 
with phytohemagglutinin-stimulated leukocytes from an NE 
patient, and PUUV antigen was not detected until 6 months 
after infection of Vero E6 cells (30).
How long after onset of disease viral hantavirus RNA 
is present in saliva and whether saliva contains neutralizing 
antibodies need to be studied further, even though ANDV-
speciﬁ  c IgA antibodies have been detected in saliva in pa-
tients with acute HCPS from 5 to 31 days after onset of 
symptoms (31). Detecting hantavirus-speciﬁ  c  antibodies 
in human saliva may be useful for diagnostics, and detect-
ing viral RNA in saliva could be used as a tool to study 
hantavirus epidemiology. ANDV RNA was shown to be 
present in human peripheral blood cells for 5 to 15 days 
before the onset of symptoms (13), and PUUV RNA was 
detected in plasma from Cynomolgus macaques 4 days be-
fore symptoms appeared (32). Studies are needed to deter-
mine whether the same is true for saliva in animal models. 
If this was the case, the hantavirus in antibody-free saliva 
could have a rather high infectious potential. On the other 
hand, saliva has antimicrobial functions (33) and has been 
shown to inhibit certain viruses, such as HIV-1 (34), inﬂ  u-
enza A virus (35), and herpes simplex virus type 1 (17); 
however, saliva does not inhibit Epstein-Barr virus (14) 
and adenovirus (34). So far, little is known regarding the 
effect of human saliva on hantavirus infectivity, but results 
of experiments we have performed indicate that human sa-
liva could reduce at least part of the infectivity in vitro (J. 
Hardestam et al., unpub. data). Apparently, hantaviruses in 
rodent saliva are infectious, but whether the composition 
of rodent and human saliva differs is not known. Further 
studies are needed to elucidate the mechanisms behind han-
tavirus transmission between the natural rodent hosts and 
humans.
After ﬁ  nding PUUV RNA in saliva from NE patients, 
we searched for evidence of possible person-to-person 
transmission of PUUV. When the NE patients were fol-
lowed-up 1–2 months later, we discovered several clusters 
of household members with NE symptoms. However, none 
had severe enough disease to require physician care, and 
no samples were collected for laboratory diagnosis. Fur-
thermore, during the large NE outbreak in early 2007, there 
was a very high incidence (313/100,000) of NE in the re-
gion where our university hospital is situated (36). Since 
all patients lived in this area, we cannot exclude inhalation 
of rodent excreta as the main or only transmission route. 
Although it remains to be clearly shown, our results sup-
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Figure. Comparison of nucleotide sequences 
between reverse transcription–PCR products 
isolated from nephropathia epidemica patients 1 
and 4. Mismatches are underlined.RESEARCH
port the hypothesis that person-to-person transmission may 
occur by this route.
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